Clinical trials: Endometriosis Associated Pelvic Pain
Dysmenorrhea
Efficacy and Safety,Long-term Study of Low-dose Oral Contraceptive Pill to Treat Dysmenorrhea.
The purpose of this long-term study is to determine whether combination oral contraceptive pill of Norethindrone \& Ethinyl estradiol is effective in the treatmentof dysmenorrhea associated with endometriosis.
- Trial name
- NCT00212277
- Testing
- Norethindrone,Ethinyl Estradiol
- Sponsor
- Nobelpharma
Endometriosis and Dysmenorrhea
Drug Use Investigation (DUI) of YazFlex for Endometriosis-associated Pelvic Pain and/or Dysmenorrhea
This study is a Japanese post-marketing surveillance (PMS) which is required by the regulatory authorities. General objective of PMS is to confirm the clinical usefulness, especially the safety profile of a drug under the routine…
- Trial name
- NCT03126747
- Testing
- BAY86-5300_YAZ-Flex
- Where
- Japan
- Volunteers
- 715 people
- Sponsor
- Bayer
Dysmenorrhea
Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Dysmenorrhea
The purpose of this study is to determine whether combination oral contraceptive pill of Norethindrone \& Ethinyl estradiol is effective in the treatment of dysmenorrhea associated with endometriosis.
- Trial name
- NCT00212342
- Testing
- Norethisterone,Ethinylestradiol, Sugar pill
- Volunteers
- 100 people
- Sponsor
- Nobelpharma
Endometriosis Associated Pelvic Pain
A Study to Learn More About How Safe Dienogest is and How Well it Works Under Real World Conditions in Indian Women With Endometriosis
Endometriosis is a condition that affects women, usually during their reproductive years. In women with endometriosis, the tissue that normally covers the inside of the womb grows outside the womb.
- Trial name
- VISAGE (NCT04808843)
- Testing
- Dienogest (BAY86-5258, Visanne)
- Where
- India
- Volunteers
- 160 people
- Sponsor
- Bayer
Endometriosis
A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain
The main objective for this study is to assess the efficacy and dose-response relationship of ASP1707 in reduction of endometriosis associated pelvic pain.
- Trial name
- NCT01767090
- Testing
- ASP1707, Leuprorelin acetate
- Where
- 85 sites in Belgium, Bulgaria and 7 more
- Volunteers
- 912 people
- Sponsor
- Astellas Pharma Europe B.V.
Pelvic Pain Associated With Endometriosis or Adenomyosis, Pelvic Pain Associated With Refractory Endometriosis
Efficacy and Tolerability of TENS in Endometriosis-related Pain
ELECTRE is a single-center, randomized, prospective, longitudinal, controlled, two-arm, single-blind study lasting 4 weeks (P1 investigation phase) after a 4-week run-in period.
- Conditions
- Pelvic Pain Associated With Endometriosis or Adenomyosis, Pelvic Pain Associated With Refractory Endometriosis, Endometriosis
- Trial name
- ELECTRE (NCT07393295)
- Testing
- Conventional TENS, Microstimulation TENS
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Monath Electronic
Endometriosis
Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain
This study was designed as a proof-of-concept trial to evaluate safety, tolerability, and the efficacy of 1800 mg (ZK 811752 600 mg given orally three times daily) over 12 weeks for the treatment of endometriosis associated…
- Trial name
- NCT00185341
- Testing
- CCR1-Antagonist (BAY86-5047, ZK811752)
- Where
- 32 sites in Czechia, Denmark and 5 more
- Volunteers
- 110 people
- Sponsor
- Bayer
Endometriosis Related Pain
SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
The purpose of this study is to determine the benefit and safety of relugolix 40 milligrams (mg) once daily, co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) compared with placebo for 24 weeks, on…
- Trial name
- NCT03204331
- Testing
- Relugolix, Estradiol/norethindrone acetate
- Where
- 91 sites in United States, Australia and 9 more
- Volunteers
- 623 people
- Sponsor
- Myovant Sciences GmbH
Endometriosis
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain
The primary objective of this extension study is to assess the maintenance of efficacy of linzagolix administered orally once daily for up to an additional 6 months (for up to 12 months of treatment in total) in women who have…
- Trial name
- EDELWEISS 5 (NCT04372121)
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.